在2025年财经网新消费·新经济年度评选中，马蜂窝凭借"AI游西江"智能体斩获"年度品类开创AI产 品"奖项，这一荣誉不仅是对其技术创新的认可，更标志着旅游平台从"内容聚合"向"AI全链路服务"的 范式升级。 传统旅游服务中，"信息碎片化""响应滞后化""体验同质化"是长期存在的行业痛点，而马蜂窝"AI游西 江"的核心创新，在于以技术整合打破场景壁垒，构建从行前决策到行后分享的闭环服务生态。这一创 新并非单一功能的叠加，而是基于旅游消费全流程的系统性重构，其核心竞争力体现在"精准洞察需求 —技术落地场景—体验持续优化"的完整逻辑链中。 在需求洞察层面，"AI游西江"深度锚定新一代旅行者的个性化需求与景区数字化管理痛点，将服务颗粒 度细化至"千人千面"。通过自然语言处理技术构建旅游知识图谱，涵盖西江各点位旅游资源、历史文 化、交通信息等，可精准回应景点特色、美食推荐、民俗文化等高频咨询。在行程规划上，能依据游客 的旅行时间、预算、兴趣偏好、交通方式生成详细方案，并结合实时交通、表演开放时间、游客流量等 动态信息优化调整，解决传统攻略"静态化"问题。针对景区管理痛点，其首创"分级审核+异常行为识 别"双机制的AI ...

如果说战略深耕是H&M抢占市场的"矛"，那么可持续发展就是其巩固行业地位的"盾"。作为将可持续 发展纳入核心战略的时尚企业，H&M的实践早已超越单一环保举措，形成覆盖供应链、技术创新、生 态共建的完整体系——这也是其斩获领军企业奖项的关键加分项。 在供应链脱碳领域，H&M的"绿色时尚倡议"已取得实质性成果：通过为中国10余家供应商提供低息贷 款与直接投资，每年可减少碳排放6.5万吨；参与绿色电力交易机制与绿电证书体系，加速供应链向可 再生能源转型。更具行业价值的是，其与上海电气（601727）合作的熔盐储能项目成功落地，为纺织行 业热能脱碳提供了突破性解决方案，并荣获上海市绿色低碳技术创新大赛大奖，实现了"商业价值+社 会价值"的双赢。技术创新与生态共建则彰显了其长期视野。H&M基金会通过"全球变革大奖"，持续支 持中国纺织领域的早期创新，助力突破性技术实现规模化落地，这种"赋能产业链上游"的举措，不仅提 升了自身供应链的韧性，更推动了整个行业的技术升级。从2002年发布首份可持续发展报告，到如今形 成全链条可持续体系，H&M的实践为外资企业融入中国"双碳"战略提供了典范。 领军价值凸显：为行业提供"可复制的 ...

Core Viewpoint - Club Med Mediterranean Club has been awarded the "Annual Sustainable Vacation Brand" honor for its sustainable practices and the implementation of the "Happy to Care" strategy, highlighting its role as a model for ecological, social, and economic value coexistence in the tourism industry amid the "dual carbon" goals and ESG transformation [1] Group 1: Sustainable Strategy - The sustainable ethos of Club Med dates back to its founding, with a clear development trajectory from social responsibility to environmental practices over 75 years [2] - The "Happy to Care" strategy encompasses three dimensions: eco-friendly vacation experiences, sustainable resorts, and positive social impact, aligning with global sustainability goals and China's "green tourism" policy [2] - The brand aims to establish partnerships with local ecological organizations by 2030, having already launched 44 ecological cooperation projects across 31 resorts by 2023 [2] Group 2: Guest Participation and Environmental Education - As of 2023, 59% of Club Med resorts have introduced "green activities," with local experiences designed to educate guests about ecology [3] - The "Bye Bye Plastic" initiative has replaced single-use plastics in guest rooms by 2023, with a target to reduce global plastic bottle usage by 35% by 2024 compared to 2019 [3] - Over 60% of fresh ingredients are sourced locally, supporting local agriculture and reducing transportation carbon footprints [3] Group 3: Certification and Standards - By 2024, 89% of Club Med resorts globally have achieved the Green Globe certification, indicating a high level of sustainable operation [4] - 73% of new and renovated resorts have received BREEAM ecological certification, with notable projects setting benchmarks for green building in the industry [4] Group 4: Climate Action and Community Engagement - Club Med has set a target to reduce building carbon emissions by 50% by 2030 compared to 2023 levels, aligning with China's dual carbon strategy [5] - The "Green Farmer" initiative has provided training to local farmers, resulting in nearly 240 tons of fresh produce supplied to resorts, benefiting over 650 farmers [5] - The integration of ESG principles into the brand's core operations reflects a long-term commitment to sustainable development [6] Group 5: Future Directions - Club Med will continue to deepen its ecological protection and community coexistence practices under the "Happy to Care" strategy, providing a model for achieving both commercial and social value in the global vacation industry [6]

Core Viewpoint - The announcement by Hutchison China MediTech regarding the acceptance of the new drug application for Fruquintinib for advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusion or rearrangement has been prioritized for review by the National Medical Products Administration of China [1] Company Summary - Hutchison China MediTech has developed Fruquintinib, a novel selective oral inhibitor targeting FGFR1, 2, and 3 [1] - The drug is aimed at adult patients who have previously undergone systemic treatment and have specific genetic markers related to their cancer [1] Industry Summary - Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy originating from the intrahepatic bile duct epithelium, accounting for approximately 8.2% to 15.0% of primary liver cancers, making it the second most common type after hepatocellular carcinoma [1] - The incidence of ICC has been on the rise, with a five-year overall survival rate of about 9% [1] - Approximately 10-15% of global ICC patients have FGFR2 fusion or rearrangement, indicating a specific target population for Fruquintinib [1]

Core Insights - JD Home Services plans to gradually launch a diverse range of elderly care service products, including assistance with bathing, short-term care, and long-term in-home care, aiming to cultivate professionals with comprehensive caregiving skills to provide standardized, regulated, and safe home and community elderly care services [1][2] Group 1: Training and Development - JD Home Services has officially opened the largest home service training base in the industry in Wanzhou, Chongqing, covering an area of approximately 20,000 square meters, utilizing an innovative "scenario-based teaching + accommodation integration" training model, and has introduced specialized courses in elderly care [1] - The company plans to invest 1 billion yuan in training and development over the next three years, focusing on high-standard elderly care course development, enhancing the training of elderly service professionals, and launching standardized and safe elderly care services [1] - JD Home Services will introduce AI teaching assistants and VR training methods, establish over 150 standardized training bases, and form a teacher team of 1,000 people, while building a comprehensive management system that integrates training management, employment matching, and quality tracking to improve training efficiency and service quality [1] Group 2: Course Offerings - The elderly care specialty courses offered by JD Home Services will cover standard operating procedures for elderly daily living assistance (including diet, daily activities, and bathing), health monitoring processes (vital sign measurement and standardized recording), emergency response processes (such as falls and sudden illnesses), psychological care processes for the elderly, and home rehabilitation processes (home-based physical rehabilitation training) [1]

(吉祥航空) 近日，吉祥航空（603885）拟与空中客车公司(以下简称"空客")签订《飞机购买协议》。根据该协议， 吉祥航空向空客购买25架空客A320系列飞机，经国家批准认可后，空客将于2028年至2032年分批向吉 祥航空交付上述飞机。 ...

目前，临床研究正在按照方案进行后续观察。此前，REC610在菲律宾和中国的探索性临床研究中均取 得了预期的结果，显示出良好的安全性和免疫应答能力。 带状疱疹是一种由潜伏感染的病毒引起的常见疾病，中国每年约有600万人罹患此病，且发病逐渐年轻 化。 （瑞科生物公告） 近日，瑞科生物发布公告称，公司新佐剂重组带状疱疹疫苗REC610的新药上市申请已于近日获得国家 药品监督管理局药品审评中心正式受理，受理号为CXSS2500145。 REC610搭载公司自主研发的BFA01新型佐剂，能够促进机体产生高水平的VZV糖蛋白E(gE)特异性 CD4+T细胞和抗体。该疫苗在2023年10月获得了国家药品监督管理局签发的药物临床试验批准通知 书，并预计于2024年12月完成III期临床全部受试者的入组。 ...

（悦康药业公告） (编辑：杨燕 林辰)关键字： 医疗 近日，悦康药业集团股份有限公司发布公告称，公司已于2025年12月29日向香港联合交易所有限公司 （以下简称"香港联交所"）递交了发行境外上市外资股（H股）并在香港联交所主板挂牌上市（以下简 称"本次发行上市"）的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。 该申请资料为公司按照香港证券及期货事务监察委员会（以下简称"香港证监会"）及香港联交所的要求 编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任 何投资决定。 ...

根据处罚决定，ST人福被给予警告并罚款850万元，当代集团合计罚款900万元；艾路明因组织领导相 关违法行为，被罚款390万元且7年不得从事证券相关业务；时任ST人福董事长李杰、财务总监吴亚君 分别被罚390万元、340万元，另有8名时任董监高分别被处以50万至250万元不等罚款。 经监管查明，2020年至2022年期间，ST人福（600079）及当代集团存在多项违法事实：一是非经营性 资金占用累计127.85亿元未及时披露，且2020年年度报告遗漏该信息；二是2022年3月下属子公司与关 联方16.45亿元物业资产交易未及时披露，且未载入当年年报；三是2020年至2022年半年度多份财报存 在虚假记载，累计虚增归母净利润超3亿元；四是当代集团隐瞒关联关系，导致公司1亿元股权收购交易 未按规定披露关联信息。 近日，人福医药发布公告称，公司及原控股股东武汉当代科技产业集团股份有限公司（下称"当代集 团"）等12名相关责任人，因信息披露违法违规收到湖北证监局《行政处罚决定书》，合计罚款超2900 万元，时任当代集团实际负责人艾路明被采取7年市场禁入措施。 公告显示，ST人福目前已触及其他风险警示，但未触及重大违法 ...

在协议生效后的 10 个工作日内，奥赛康药业将向阿诺医药支付 3500 万元人民币的一次性、不可退还、 不可抵扣的首付款。并在产品研发、注册及上市的各阶段支付不超过4.7亿元人民币的里程碑付款，销 售里程碑事件达成相关付款总计不超过11.28亿元人民币。此外，产品在许可区域内实现商业销售后， 奥赛康药业将支付年度净销售额的梯度特许权使用费。 （奥赛康公告） AN9025 项目是阿诺医药开发的新型口服泛 RAS 抑制剂，能够同时结合活化的 RAS-GTP 和分子伴侣 （亲环素 A）形成三元复合物，高效抑制多种类型的KRAS、NRAS 及 HRAS 突变。AN9025 项目拟用 于治疗 RAS 突变型实体瘤，已在中国和美国完成新药临床试验申请（IND），并已获得了美国食品药 品监督管理局（FDA）的临床试验批准。 近日，奥赛康（002755）发布公告称，公司子公司江苏奥赛康药业有限公司与杭州阿诺生物医药科技有 限公司达成许可引进协议，根据协议，奥赛康药业将获得阿诺医药在研的1类创新药AN9025项目在许可 区域内的开发、生产及商业化的独占权益。 ...